Trial Profile
Multicenter Clinical Trial Evaluating the Immunological Response of Vaccination Against Infection by Human Papillomavirus (HPV) 6, 11, 16, 18 in Girls Receiving Immunosuppressive Therapy.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Jul 2017
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary) ; Corticosteroids; Immunosuppressants
- Indications Cervical cancer; Cervical dysplasia; Genital warts; Human papillomavirus infections; Vulvar dysplasia
- Focus Therapeutic Use
- Acronyms PRIMAVERA
- 30 Jul 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
- 12 Dec 2013 Planned end date changed from 1 Aug 2016 to 1 Nov 2016 as reported by ClinicalTrials.gov.
- 12 Dec 2013 Planned number of patients changed from 35 to 37 as reported by ClinicalTrials.gov.